NovaDel may seek bankruptcy protection, even as it regains rights to anti-emetic
This article was originally published in Scrip
Executive Summary
The US specialty company NovaDel Pharma announced on 18 January that it may not have adequate cash to continue operation beyond the end of January 2012. Two days later, it said it terminated certain licence agreements with Talon Therapeutics and Par for its oral spray formulation of the off-patent anti-emetic ondansetron, Zensana, in the US and Canada. The investigational candidate was in preclinical development.